Addition of Motesanib to Chemotherapy Offers No Benefit for Patients With Non–Small Cell Lung Cancer
Published Online: Tuesday, November 27, 2012
Giorgio V. Scagliotti, MD
The data also showed that the agent did not prolong OS in a subset of patients with adenocarcinoma histology. Giorgio V. Scagliotti, MD, professor of Medicine at the University of Turin, and colleagues elsewhere randomized 1090 patients to carboplatin (area under the curve, 6 mg/mL/min) and paclitaxel (200 mg/m2) intravenously for up to six 3-week cycles plus once-daily oral motesanib (125 mg) or placebo.
Study participants had stage IIIB/IV or recurrent nonsquamous NSCLC and had not undergone systemic therapy for advanced disease.
Motesanib is an oral, small-molecule targeted antagonist of VEGF receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit. The agent has shown antitumor activity in NSCLC patients when administered alone or combined with chemotherapy.
The study’s primary endpoint was OS. The median OS in the motesanib group was 13.0 months versus 11.0 months for the placebo group (hazard ratio [HR] = 0.90; 95% CI, 0.78-1.04; P = .14). In the subset of 890 patients with adenocarcinoma, the median OS was 13.5 months with motesanib and 11.0 months with placebo (HR = 0.88; 95% CI, 0.75-1.03; P = .11).
In all patients with nonsquamous histology, the median progression-free survival (PFS) time was 5.6 months for motesanib and 5.4 months for placebo, respectively (P <.001). The overall response rates (ORR) were 40% versus 26% (P <.001). PFS and ORR were secondary study endpoints.
Phase III MONET1 Trial Results
|Treatment||Median OS||Median PFS||ORR|
|Motesanib + Carboplatin/ Paclitaxel||13.0 mo||5.6 mo||40%|
|Carboplatin/ Paclitaxel||11.0 mo||5.4 mo||26%|
Mo indicates months; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.
A prespecified ethnicity/regional subanalysis revealed that Asian patients, who comprised 25% of the enrolled study population, were the only subset of patients who had improved OS from motesanib.
Serious adverse effects occurred in 49% of patients in the motesanib arm versus 34% in the chemotherapy-only arm. Motesanib-treated patients had an increased incidence of diarrhea, nausea, vomiting, abdominal pain, hypertension, proteinuria, stomatitis, gallbladder disorders, neutropenia, and thrombocytopenia.
The investigators found no association between levels of placental growth factor (PLGF) and response rate or survival. PLGF, which is a VEGF homolog that can promote angiogenesis by activating VEGF receptor 1, had been shown to increase in response to motesanib in a prior phase II study.
Scagliotti et al said that their findings bolster mounting evidence suggesting that VEGF pathway inhibitors in tandem with chemotherapy do not offer significant benefit to unselected patients with nonsquamous NSCLC. More studies with these agents are not likely to be fruitful without improved patient selection using biomarkers.
Scagliotti GV, Vynnychenko I, Park K, et al. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non–small-cell lung cancer: MONET1. J Clin Oncol. 2012;30(23):2829-2836.
Online CME Activities
Most Popular Right Now